|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection 显示文摘 | Dusci LJ Peter Hackett L Fellows LM | 2002 | J Chromatogr B: Anal Technol Biomed Life Sci2002，773，： | 1 |
| 2 | Determina- tion of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection显示文摘 | Dusci L J Peter Hackett L Fellows L M | 2002 | Journal of Chromatography B2002，773，2： | 1 |
| 3 | Cyclic 3′,5′-adenosine monophosphate modulates retinal pigment epithelil cell migration in vitro显示文摘 | Hackett S friedman Z Peter A | 1986 | Arch Ophthalmol1986，104，： | 1 |
| 4 | Life on the Qinghai-Tibetan plateau显示文摘 | Ge Rili Peter Hackett | 2007 | Peking University Medical Press2007，，7： | 1 |
| 5 | High altitude illness显示文摘 | Peter H Hackett MD Rober C | 2001 | N Eng J Med2001，345，2： | 1 |
| 6 | Allen,The Further Appraise of Bass's Transactional Leaders and Transformational Leaders显示文摘 | Peter Bycio、Rick D Hackett、Joyce S | 1995 | Journal of Applied Sychology1995，，4： | 1 |
| 7 | The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease显示文摘 | Ajay Nehra Graham Jackson Martin Miner Kevin L. Billups Arthur L. Burnett Jacques Buvat Culley C. Carson Glenn R. Cunningham Peter Ganz Irwin Goldstein Andre T. Guay Geoff Hackett Robert A. Kloner John Kostis Piero Montorsi Melinda Ramsey Raymond Rosen Ri | 2012 | Mayo Clinic Proceedings2012，，8： | 1 |
| 8 | High altitude illness显示文摘 | Peter H Hackett MD Rober C | 2001 | N Eng J Med2001，345，2： | 1 |
| 9 | Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor显示文摘 | Katsuaki Miki Akiko Miki Masato Matsuoka Daisuke Muramatsu Sean F. Hackett Peter A. Campochiaro | 2009 | Ophthalmology2009，，9： | 1 |
| 10 | Life on the Qinghai-Tibetan plateau 显示文摘 | Ge Ri-Li Peter Hackett | 2007 | Peking University Medical Press2007，7，： | 1 |
| 11 | Acute Mountain Sickness显示文摘 | Peter Hackett Drummond Rennie | 1983 | Semin Respir Crit Care Med1983，，02： | 1 |
| 12 | 腹腔镜手术时腹腔内注射哌替啶和罗哌卡因后的药物分布与临床作用显示文摘背景目前,支持腹腔内注射哌替啶或局部麻醉药以提供有效手术后镇痛的证据尚为有限。本研究的目的旨在探讨腹腔内注射哌替啶和罗哌卡因后镇痛的有效性,并测定药物的血浆浓度。本研究的无效假设为:各组患者接受腹腔镜腹部大手术后24小时内活动时疼痛程度无统计学差异。方法本研究采用随机、双盲和空白对照的方法,在2个医学中心将250例拟行腹腔镜手术的女性患者分为5组:腹腔内注射哌替啶50或100mg(M50和M100组)、罗哌卡因150mg(R150组)、哌替啶50mg复合罗哌卡因150mg(M50R150组)和哌替啶肌肉注射50mg(对照组)。所有患者均肌肉注射生理盐水或腹腔内注射生理盐水,以保证各组处理方法的一致性。在恢复期间,将疼痛作为基本的观察指标,此后还要测定药代动力学参数。结果各组患者在手术后恢复室中及离开后的活动疼痛评分均数差异无统计学意义[对照组、M50组、M100组、R150组和M50R150组分别为2.2(2.8)、2.5(3.3)、1.6(2.5)、2.6(3.2)和2.7(3.2),P=0.50]。各组问静息疼痛评分、吗啡静脉用量、恢复指标和患者满意度的差异无统计学意义。腹腔内给予哌替啶50mg后,其血浆浓度(中位数55~60ug/L)相当于肌肉注射等量哌替啶后血浆浓度的一半(中位数113ug/L)。结论与全身注射阿片类药物相比,腹腔内注射哌替啶和罗哌卡因(单独使用或联合使用)并不能更好地缓解腹腔镜手术后的疼痛或减少阿片类药物的使用量。 | Michael J. Paech Kenneth F. Itett Peter Hackett Madhu Page-Sharp Richard W. Parsons 邢军(译) 李成辉(校) | 2009 | 麻醉与镇痛2009，，1： | 0 |
| 13 | Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes显示文摘AIM To determine how statins, testosterone(T) replacement therapy(TRT) and phosphodiesterase 5-inhibitors(PDE5I) influence age related mortality in diabetic men.METHODS We studied 857 diabetic men screened for the BLAST study, stratifying them(mean follow-up = 3.8 years) into:(1) Normal T levels/untreated(total T > 12 nmol/L and free T > 0.25 nmol/L), Low T/untreated and Low T/treated;(2) PDE5I/untreated and PDE5I/treated; and(3) statin/untreated and statin/treated groups. The relationship between age and mortality, alone and with T/TRT, statin and PDE5 I treatment was studied using logistic regression. Mortality probability and 95%CI were calculated from the above models for each individual. RESULTS Age was associated with mortality(logistic regression, OR = 1.10, 95%CI: 1.08-1.13, P < 0.001). With all factors included, age(OR = 1.08, 95%CI: 1.06-1.11, P < 0.001), Low T/treated(OR = 0.38, 95%CI: 0.15-0.92, P = 0.033), PDE5I/treated(OR = 0.17, 95%CI: 0.053-0.56, P = 0.004) and statin/treated(OR = 0.59, 95%CI: 0.36-0.97, P = 0.038) were associated with lower mortality. Age related mortality was as described by Gompertz, r2 = 0.881 when Ln(mortality) was plotted against age. The probability of mortality and 95%CI(from logistic regression) of individuals, treated/untreated with the drugs, alone and in combination was plotted against age. Overlap of 95%CI lines was evident with statins and TRT. No overlap was evident with PDE5 I alone and with statins and TRT, this suggesting a change in the relationship between age and mortality. CONCLUSION We show that statins, PDE5 I and TRT reduce mortality in diabetes. PDE5 I, alone and with the other treatments significantly alter age related mortality in diabetic men. | Geoffrey Hackett Peter W Jones Richard C Strange Sudarshan Ramachandran | 2017 | World Journal of Diabetes2017，8，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员